A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib

被引：9

作者：

Lim, Chloe A. ^{[1
,2
]}

Banyi, Norbert ^{[1
,3
]}

Tucker, Tracy ^{[4
]}

Ionescu, Diana N. ^{[3
]}

Melosky, Barbara ^{[5
]}

机构：

[1] Univ British Columbia, Fac Med, MD Undergrad Program, Vancouver, BC V6T 1Z1, Canada

[2] Univ Calgary, Internal Med Residency Program, Calgary, AB T2N 1N4, Canada

[3] BC Canc, Dept Pathol, Vancouver, BC V6T 1Z1, Canada

[4] BC Canc, Dept Pathol & Lab Med, Canc Genet & Genom Lab, Vancouver, BC V6T 1Z1, Canada

[5] BC Canc, Med Oncol, Vancouver, BC V6T 1Z1, Canada

来源：

CURRENT ONCOLOGY | 2022年 / 29卷 / 02期

关键词：

neuroendocrine; adenocarcinoma; driver mutation; ALK; LCNEC; CHEMOTHERAPY; IDENTIFICATION; RESISTANCE;

D O I：

10.3390/curroncol29020072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report a rare case of stage IV pulmonary combined large-cell neuroendocrine carcinoma (LCNEC) and adenocarcinoma (ACA), both demonstrating anaplastic lymphoma kinase (ALK) rearrangement by IHC and FISH. This 61-year-old lifelong nonsmoking Asian woman presented with a cough, and after diagnosis and surgical treatment, completed four cycles of adjuvant cisplatin and etoposide chemotherapy. She subsequently developed recurrence with bony metastases of exclusively ALK-positive LCNEC. Alectinib was started, and the patient experienced a partial response.

引用

页码：848 / 852

页数：5

共 17 条

[1] Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma [J].

Caumont, Charline ;

Veillon, Remi ;

Gros, Audrey ;

Laharanne, Elodie ;

Begueret, Hugues ;

Merlio, Jean-Philippe .

LUNG CANCER, 2016, 92 :15-18

[2] ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases [J].

Fares, Aline F. ;

Lok, Benjamin H. ;

Zhang, Tong ;

Cabanero, Michael ;

Lau, Sally C. M. ;

Stockley, Tracy ;

Patel, Devalben ;

Bradbury, Penelope A. ;

Sacher, Adrian ;

Yasufuku, Kazuhiro ;

Morash, Barbara A. ;

Sabatini, Peter J. B. ;

Nguyen, Lananhn N. ;

Leighl, Natasha B. ;

Tsao, Ming-Sound ;

Shepherd, Frances A. ;

Liu, Geoffrey ;

Martins-Filho, Sebastiao N. ;

Pal, Prodipto .

LUNG CANCER, 2020, 146 :350-354

[3] Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib [J].

Hayashi, Nobuyoshi ;

Fujita, Akihisa ;

Saikai, Toyohiro ;

Takabatake, Hirotugu ;

Sotoshiro, Mie ;

Sekine, Kyuutarou ;

Kawana, Akihiko .

INTERNAL MEDICINE, 2018, 57 (05) :713-716

[4] Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors [J].

Hoton, Delphine ;

Humblet, Yves ;

Libbrecht, Louis .

HISTOPATHOLOGY, 2018, 72 (04) :707-710

[5] Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma [J].

Iyoda, Akira ;

Hiroshima, Kenzo ;

Moriya, Yasumitsu ;

Takiguchi, Yuichi ;

Sekine, Yasuo ;

Shibuya, Kiyoshi ;

Iizasa, Toshihiko ;

Kimura, Hideki ;

Nakatani, Yukio ;

Fujisawa, Takehiko .

ANNALS OF THORACIC SURGERY, 2006, 82 (05) :1802-1807

[6] Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206 [J].

Kenmotsu, Hirotsugu ;

Niho, Seiji ;

Tsuboi, Masahiro ;

Wakabayashi, Masashi ;

Ishii, Genichiro ;

Nakagawa, Kazuo ;

Daga, Haruko ;

Tanaka, Hiroshi ;

Saito, Haruhiro ;

Aokage, Keiju ;

Takahashi, Toshiaki ;

Menju, Toshi ;

Kasai, Takashi ;

Yoshino, Ichiro ;

Minato, Koichi ;

Okada, Morihito ;

Eba, Junko ;

Asamura, Hisao ;

Ohe, Yuichiro ;

Watanabe, Shun-ichi .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (36) :4292-+

[7] Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study [J].

Le Treut, J. ;

Sault, M. C. ;

Lena, H. ;

Souquet, P. J. ;

Vergnenegre, A. ;

Le Caer, H. ;

Berard, H. ;

Boffa, S. ;

Monnet, I. ;

Damotte, D. ;

Chouaid, C. .

ANNALS OF ONCOLOGY, 2013, 24 (06) :1548-1552

[8] RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis [J].

Litiere, Saskia ;

Isaac, Gaelle ;

De Vries, Elisabeth G. E. ;

Bogaerts, Jan ;

Chen, Alice ;

Dancey, Janet ;

Ford, Robert ;

Gwyther, Stephen ;

Hoekstra, Otto ;

Huang, Erich ;

Lin, Nancy ;

Liu, Yan ;

Mandrekar, Sumithra ;

Schwartz, Lawrence H. ;

Shankar, Lalitha ;

Therasse, Patrick ;

Seymour, Lesley .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) :1102-+

[9] Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma [J].

Nakamura, Harumi ;

Tsuta, Koji ;

Yoshida, Akihiko ;

Shibata, Tatsuhiro ;

Wakai, Susumu ;

Asamura, Hisao ;

Furuta, Koh ;

Tsuda, Hitoshi .

JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (08) :705-707

[10] A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4-ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib [J].

Omachi, Naoki ;

Shimizu, Shigeki ;

Kawaguchi, Tomoya ;

Tezuka, Kenji ;

Kanazu, Masaki ;

Tamiya, Akihiro ;

Asami, Kazuhiro ;

Okishio, Kyoichi ;

Kitaichi, Masanori ;

Atagi, Shinji .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (06) :E40-E42

← 1 2 →